Zhang Xiaoyi, Luo Gang
Department of Biomedical Informatics and Medical Education, University of Washington, Seattle, WA, United States.
JMIR Med Inform. 2022 Jun 8;10(6):e38220. doi: 10.2196/38220.
Asthma hospital visits, including emergency department visits and inpatient stays, are a significant burden on health care. To leverage preventive care more effectively in managing asthma, we previously employed machine learning and data from the University of Washington Medicine (UWM) to build the world's most accurate model to forecast which asthma patients will have asthma hospital visits during the following 12 months.
Currently, two questions remain regarding our model's performance. First, for a patient who will have asthma hospital visits in the future, how far in advance can our model make an initial identification of risk? Second, if our model erroneously predicts a patient to have asthma hospital visits at the UWM during the following 12 months, how likely will the patient have ≥1 asthma hospital visit somewhere else or ≥1 surrogate indicator of a poor outcome? This work aims to answer these two questions.
Our patient cohort included every adult asthma patient who received care at the UWM between 2011 and 2018. Using the UWM data, our model made predictions on the asthma patients in 2018. For every such patient with ≥1 asthma hospital visit at the UWM in 2019, we computed the number of days in advance that our model gave an initial warning. For every such patient erroneously predicted to have ≥1 asthma hospital visit at the UWM in 2019, we used PreManage and the UWM data to check whether the patient had ≥1 asthma hospital visit outside of the UWM in 2019 or any surrogate indicators of poor outcomes. Such surrogate indicators included a prescription for systemic corticosteroids during the following 12 months, any type of visit for asthma exacerbation during the following 12 months, and asthma hospital visits between 13 and 24 months later.
Among the 218 asthma patients in 2018 with asthma hospital visits at the UWM in 2019, 61.9% (135/218) were given initial warnings of such visits ≥3 months ahead by our model and 84.4% (184/218) were given initial warnings ≥1 day ahead. Among the 1310 asthma patients in 2018 who were erroneously predicted to have asthma hospital visits at the UWM in 2019, 29.01% (380/1310) had asthma hospital visits outside of the UWM in 2019 or surrogate indicators of poor outcomes.
Our model gave timely risk warnings for most asthma patients with poor outcomes. We found that 29.01% (380/1310) of asthma patients for whom our model gave false-positive predictions had asthma hospital visits somewhere else during the following 12 months or surrogate indicators of poor outcomes, and thus were reasonable candidates for preventive interventions. There is still significant room for improving our model to give more accurate and more timely risk warnings.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): RR2-10.2196/5039.
哮喘患者的医院就诊,包括急诊就诊和住院治疗,给医疗保健带来了沉重负担。为了在哮喘管理中更有效地利用预防性护理,我们之前利用机器学习和华盛顿大学医学中心(UWM)的数据构建了世界上最准确的模型,以预测哪些哮喘患者在接下来的12个月内会有哮喘相关的医院就诊。
目前,关于我们模型的性能仍存在两个问题。第一,对于未来会有哮喘相关医院就诊的患者,我们的模型能提前多久首次识别出风险?第二,如果我们的模型错误地预测一名患者在接下来的12个月内在UWM会有哮喘相关医院就诊,那么该患者在其他地方有≥1次哮喘相关医院就诊或有≥1个不良结局替代指标的可能性有多大?这项工作旨在回答这两个问题。
我们的患者队列包括2011年至2018年期间在UWM接受治疗的每一位成年哮喘患者。利用UWM的数据,我们的模型对2018年的哮喘患者进行了预测。对于每一位在2019年在UWM有≥1次哮喘相关医院就诊的此类患者,我们计算了我们的模型提前发出初始警告的天数。对于每一位在2019年被错误预测在UWM有≥1次哮喘相关医院就诊的此类患者,我们使用PreManage和UWM的数据来检查该患者在2019年是否在UWM以外的地方有≥1次哮喘相关医院就诊或有任何不良结局替代指标。此类替代指标包括在接下来的12个月内开具全身性皮质类固醇的处方、在接下来的12个月内因哮喘加重进行的任何类型就诊,以及13至24个月后哮喘相关医院就诊。
在2018年有2019年在UWM哮喘相关医院就诊的218例哮喘患者中,我们的模型提前≥3个月对此类就诊发出初始警告的占61.9%(135/218),提前≥天发出初始警告的占84.4%(184/218)。在2018年被错误预测在2019年在UWM有哮喘相关医院就诊的1310例哮喘患者中,29.01%(380/1310)在2019年在UWM以外的地方有哮喘相关医院就诊或有不良结局替代指标。
我们的模型为大多数预后不良的哮喘患者及时发出了风险警告。我们发现,我们的模型给出假阳性预测的哮喘患者中有29.01%(380/1310)在接下来的12个月内在其他地方有哮喘相关医院就诊或有不良结局替代指标,因此是预防性干预的合理候选对象。我们的模型在提供更准确、更及时的风险警告方面仍有很大的改进空间。
国际注册报告识别号(IRRID):RR2-10.2196/5039 。